Biotricity, Inc. (BTCY) Cash Flow Statement
Where BTCY’s cash came from and went, FY2026
March 31, 2026 · U.S. dollars- Cash from operations
- −$718,955
- Capital expenditures
- $0 0.0% of revenue
- Free cash flow
- −$718,955 −4.5% margin
- Returned to shareholders
- $224,033
- Change in cash
- −$215,356 cash at year-end $149,789
Drawn to scale: where the cash came from and how it was used. Hover for values.
BTCY operating cash flow, capex and free cash flow
BTCY cash flow trends, FY2017–FY2026
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$3.7MFY2017 | −$718,955FY2026 | — | |
| Capital expenditures | $0FY2017 | $0FY2026 | — | |
| Free cash flow | −$3.7MFY2017 | −$718,955FY2026 | — | |
| Free cash flow margin | −1,311.1%FY2019 | −4.5%FY2026 | +1,306.6 pts | |
| Stock-based compensation | $626,136FY2017 | $25,632FY2026 | −29.9%/yr | |
| Dividends paid | $180,000FY2017 | $24,033FY2026 | −20.0%/yr | |
| Share buybacks (net) | $0FY2017 | $200,000FY2026 | — | |
| Capex / revenue | 7.5%FY2019 | 0.0%FY2026 | −7.5 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
BTCY cash flow by activity
BTCY net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
BTCY cash flow statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$2.4M | −$8.4M | −$14.1M | −$18.7M | −$29.1M | −$15.5M | −$11.1M | −$8.6M | −$8.6M | −$7.8M |
| Depreciation & amortization | $751,849 | $5,953 | $2.2M | $5,953 | $2,308 | $2.5M | $148,764 | $8.6M | $7.7M | $5.9M |
| Stock-based compensation | $25,632 | $1.5M | $1.0M | $647,631 | $913,613 | $790,535 | $2.4M | $1.5M | $1.0M | $626,136 |
| Change in working capital | $180,808 | $962,229 | $3.7M | $2.3M | −$117,583 | −$627,902 | −$286,505 | $307,091 | −$431,663 | −$327,479 |
| Other non-cash items | $726,895 | $3.6M | $518,824 | $2.1M | $13.2M | $1.8M | $933,191 | −$7.0M | −$4.5M | −$2.2M |
| Cash from operating activities | −$718,955 | −$2.4M | −$6.7M | −$13.5M | −$15.2M | −$11.1M | −$7.9M | −$5.2M | −$4.9M | −$3.7M |
| Investing activities | ||||||||||
| Capital expenditures | $0 | −$3 | $0 | −$5 | −$29,767 | −$29,767 | −$29,767 | −$29,767 | $0 | $0 |
| Investments (net) | — | — | — | −$1 | −$29,767 | $0 | — | — | — | — |
| Acquisitions & other investing | — | — | — | — | $29,767 | $0 | $0 | $0 | — | — |
| Cash from investing activities | — | — | — | — | −$29,767 | −$29,767 | −$29,767 | −$29,767 | — | — |
| Financing activities | ||||||||||
| Dividends paid | −$24,033 | −$29,984 | −$18,016 | −$946,780 | −$966,110 | −$602,969 | −$180,000 | −$180,000 | −$180,000 | −$180,000 |
| Share repurchases & issuance (net) | −$200,000 | $0 | $0 | −$895,556 | −$230,000 | $267,941 | — | — | — | $5.5M |
| Net borrowing (repayment) | $781,769 | $101,484 | $3.8M | $3.8M | $10.6M | $12.5M | $1.2M | $867,699 | $867,699 | $2.6M |
| Shares issued | $0 | $1.9M | $2.9M | $2.0M | $14.9M | $200,000 | $7.9M | $3.6M | $0 | $0 |
| Other financing | $0 | $0 | $0 | −$2.0M | $872,292 | −$200,000 | −$1 | $230,835 | $4.6M | −$3.9M |
| Cash from financing activities | $557,736 | $1.9M | $6.7M | $2.0M | $25.2M | $12.2M | $8.9M | $4.6M | $5.3M | $4.0M |
| Summary | ||||||||||
| Net change in cash | −$215,356 | −$420,915 | $215,600 | −$11.5M | $9.9M | $1.3M | $886,201 | −$779,996 | $418,775 | $371,225 |
| Cash at end of period | $149,789 | $365,145 | $786,060 | $570,460 | $12.1M | $2.2M | $949,848 | $63,647 | $843,643 | $424,868 |
| Free cash flow | −$718,955 | −$2.4M | −$6.7M | −$13.5M | −$15.2M | −$11.1M | −$7.9M | −$5.2M | −$4.9M | −$3.7M |
| Free cash flow margin | −4.5% | −17.3% | −55.5% | −140.6% | −198.6% | −327.4% | −554.6% | −1,311.1% | — | — |
| Capex / revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.4% | 0.9% | 2.1% | 7.5% | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$959,468 | −$324,182 | −$717,067 | −$690,913 | −$671,977 | −$1.9M | −$1.2M | −$1.6M | −$3.7M | −$4.2M | −$2.8M | −$3.7M |
| Depreciation & amortization | $324,426 | $1,488 | $1,488 | $1,489 | $1,488 | $1,488 | $1,488 | $1,489 | $1,488 | $96,030 | $94,525 | $1,488 |
| Stock-based compensation | $339,970 | $7,695 | $6,001 | $6,001 | $5,935 | $1.3M | $56,939 | $56,885 | $58,978 | $481,275 | $170,140 | $163,335 |
| Change in working capital | $692,248 | −$31,875 | −$517,800 | $773,638 | $9,956 | −$559,553 | $672,563 | $696,395 | $152,823 | $2.0M | $444,272 | $377,782 |
| Other non-cash items | $110,051 | $325,969 | $487,087 | $325,415 | $281,209 | $804,121 | $410,071 | $409,940 | $2.0M | $409,705 | $793,188 | $758,199 |
| Cash from operating activities | $507,227 | −$20,905 | −$740,291 | $415,630 | −$373,389 | −$400,785 | −$88,093 | −$397,059 | −$1.5M | −$1.2M | −$1.3M | −$2.4M |
| Investing activities | ||||||||||||
| Capital expenditures | −$5 | $0 | $0 | $0 | −$5 | $0 | −$3 | $0 | $0 | $0 | −$4 | −$4 |
| Financing activities | ||||||||||||
| Dividends paid | −$6,000 | −$6,000 | −$6,000 | −$6,115 | −$5,918 | −$6,116 | −$5,852 | −$6,049 | −$11,967 | $0 | −$6,049 | −$5,918 |
| Share repurchases & issuance (net) | $0 | $0 | $0 | −$200,000 | $0 | — | $0 | — | — | $0 | $0 | $0 |
| Net borrowing (repayment) | −$184,935 | −$85,546 | $727,325 | −$301,633 | $441,623 | $171,130 | $430,812 | $57,148 | — | — | — | — |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $7 | $0 | $420,000 | $1.4M | $925,000 | $0 | $2.0M |
| Other financing | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | −$557,606 | $863,504 | $200,596 | $1.4M |
| Cash from financing activities | −$190,935 | −$91,546 | $721,325 | −$507,748 | $435,705 | $165,021 | $424,960 | $471,099 | $868,180 | $1.8M | $194,547 | $3.4M |
| Summary | ||||||||||||
| Net change in cash | $316,714 | −$101,199 | −$52,103 | −$82,832 | $26,147 | −$235,765 | $336,332 | $72,539 | −$685,329 | $700,966 | −$1.1M | $1.1M |
| Cash at end of period | $466,503 | $149,789 | $256,357 | $308,460 | $391,292 | $365,145 | $509,602 | $173,270 | $100,731 | $786,060 | $85,094 | $1.2M |
| Free cash flow | $507,227 | −$20,905 | −$740,291 | $415,630 | −$373,389 | −$400,785 | −$88,093 | −$397,059 | −$1.5M | −$1.2M | −$1.3M | −$2.4M |
| Free cash flow margin | 11.9% | −0.5% | −18.6% | 10.7% | −9.6% | −10.8% | −2.4% | −12.2% | −46.7% | −36.7% | −43.9% | −82.7% |
| Capex / revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
BTCY cash generation
In fiscal 2026 (ended March 31, 2026), Biotricity generated -$0.7 million of cash from operations and spent $0 on capital expenditures, leaving free cash flow of -$0.7 million, −4.5% of revenue. It returned $0.2 million to shareholders through dividends ($0.0 million) and net share buybacks ($0.2 million). Cash and equivalents fell by $0.2 million over the year.
Related: BTCY income statement, BTCY balance sheet. See the BTCY stock overview for the latest quote and news.
BTCY cash flow FAQ
What is Biotricity's free cash flow?
Biotricity's free cash flow was -$0.7 million in fiscal 2026: -$0.7 million of operating cash flow minus $0 of capital expenditures It was -$2.4 million a year earlier..
How much cash does Biotricity generate from operations?
Biotricity generated -$0.7 million of cash from operating activities in fiscal 2026.
How much stock does Biotricity buy back?
Biotricity spent $0.2 million on net share repurchases in fiscal 2026.
How much does Biotricity pay in dividends?
Biotricity paid $0.0 million in dividends in fiscal 2026.